Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
36.68 BRL | +1.89% | +0.77% | +13.56% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 58% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- With an expected P/E ratio at 33.17 and 21.22 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.56% | 13.54B | - | ||
+15.19% | 121B | B+ | ||
+19.91% | 114B | B+ | ||
-19.80% | 20.43B | B+ | ||
-16.19% | 16.55B | A- | ||
-13.45% | 16.45B | B | ||
-44.35% | 15.59B | A- | ||
+66.67% | 15.19B | C+ | ||
+119.39% | 10.96B | C | ||
+19.33% | 8.15B | - | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NBIX Stock
- N1BI34 Stock
- Ratings Neurocrine Biosciences, Inc.